Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 0 | 4 | 4 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 8 | 9 |
| 2003 | 1 | 5 | 6 |
| 2004 | 2 | 9 | 11 |
| 2005 | 2 | 5 | 7 |
| 2006 | 3 | 2 | 5 |
| 2007 | 5 | 6 | 11 |
| 2008 | 7 | 8 | 15 |
| 2009 | 5 | 4 | 9 |
| 2010 | 8 | 18 | 26 |
| 2011 | 3 | 10 | 13 |
| 2012 | 9 | 16 | 25 |
| 2013 | 10 | 13 | 23 |
| 2014 | 11 | 18 | 29 |
| 2015 | 7 | 17 | 24 |
| 2016 | 17 | 12 | 29 |
| 2017 | 13 | 19 | 32 |
| 2018 | 22 | 12 | 34 |
| 2019 | 14 | 21 | 35 |
| 2020 | 14 | 16 | 30 |
| 2021 | 11 | 11 | 22 |
| 2022 | 3 | 7 | 10 |
| 2023 | 5 | 5 | 10 |
| 2024 | 11 | 7 | 18 |
| 2025 | 11 | 7 | 18 |
| 2026 | 12 | 7 | 19 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma. N Engl J Med. 2026 Sep 24; 395(12):1180-1192.
-
Ceramide-Induced Endoplasmic Reticulum Stress Reveals a Targetable Vulnerability in Endocrine Therapy-Resistant Breast Cancer. Mol Cancer Res. 2026 Sep 02; 24(9):784-800.
-
CD73 inhibition overcomes adaptive immune resistance to PARP inhibition in models of prostate cancer. J Clin Invest. 2026 Oct 01; 136(19).
-
Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers. Gynecol Oncol. 2026 Sep; 212:134-144.
-
Developing next-generation antibody-drug conjugates for breast cancer drug delivery: hurdles and advances in the clinic. Expert Opin Drug Deliv. 2026 Oct; 23(10):1761-1774.
-
Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2026 Jul 17; 32(14):3018-3030.
-
American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults. Blood Adv. 2026 Jul 14; 10(13):4726-4756.
-
Gene regulatory network analysis identifies dysregulation of hypoxia pathways as contributing to glioblastoma treatment resistance in females. Biol Sex Differ. 2026 05 21; 17(1).
-
Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trial. Nat Commun. 2026 May 08; 17(1).
-
Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure. J Ovarian Res. 2026 Apr 25; 19(1).